

HPMS E-Mail

Date: March 20, 2025

Subject: Extension of Oral Antiviral Drugs with Emergency Use Authorization (EUA) as Part D Drugs

Pursuant to section 2209 of the Continuing Appropriations and Extension Act, 2025, prescription oral antivirals for COVID-19 with emergency use authorization (EUA) are included in the definition of a Part D drug through September 30, 2025. Therefore, guidance in the December 26, 2024 memorandum, "Introduction of Prescription Oral Antivirals for COVID-19 to the Commercial Market," related to commercial EUA-labeled Lagevrio continues to apply through September 30, 2025.